HER2 therapy - Molecular mechanisms of trastuzumab resistance

被引：310

作者：

Nahta, Rita

Esteva, Francisco J.

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Breast Canc Translat Res Lab, Dept Breast Med Oncol, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Breast Canc Translat Res Lab, Houston, TX 77030 USA

[3] Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA

来源：

BREAST CANCER RESEARCH | 2006年 / 8卷 / 06期

关键词：

D O I：

10.1186/bcr1612

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. The majority of patients with metastatic breast cancer who initially respond to trastuzumab develop resistance within one year of treatment initiation, and in the adjuvant setting 15% of patients still relapse despite trastuzumab-based therapy. In this review, we discuss potential mechanisms of antitumor activity by trastuzumab, and how these mechanisms become altered to promote therapeutic resistance. We also discuss novel therapies that may improve the efficacy of trastuzumab, and that offer hope that the survival of breast cancer patients with HER2-overexpressing tumors can be vastly improved.

引用

页数：8

共 71 条

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].

Agus, DB ;

Akita, RW ;

Fox, WD ;

Lewis, GD ;

Higgins, B ;

Pisacane, PI ;

Lofgren, JA ;

Tindell, C ;

Evans, DP ;

Maiese, K ;

Scher, HI ;

Sliwkowski, MX .

CANCER CELL, 2002, 2 (02) :127-137

[2] THE TRANSFORMING POTENTIAL OF THE C-ERBB-2 PROTEIN IS REGULATED BY ITS AUTOPHOSPHORYLATION AT THE CARBOXYL-TERMINAL DOMAIN [J].

AKIYAMA, T ;

MATSUDA, S ;

NAMBA, Y ;

SAITO, T ;

TOYOSHIMA, K ;

YAMAMOTO, T .

MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (02) :833-842

[3]

ALI SM, 2006, J CLIN ONCOL, V24, P500, DOI DOI 10.1200/JCO.2006.24.18_SUPPL.500

[4] Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation [J].

Anido, Judit ;

Scaltriti, Maurizio ;

Bech Serra, Joan Josep ;

Santiago Josefat, Belen ;

Rojo Todo, Federico ;

Baselga, Jose ;

Arribas, Joaquin .

EMBO JOURNAL, 2006, 25 (13) :3234-3244

[5] Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].

Arnould, L ;

Gelly, M ;

Penault-Llorca, F ;

Benoit, L ;

Bonnetain, F ;

Migeon, C ;

Cabaret, V ;

Fermeaux, V ;

Bertheau, P ;

Garnier, J ;

Jeannin, JF ;

Coudert, B .

BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267

[6] Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2 [J].

Bali, P ;

Pranpat, M ;

Swaby, R ;

Fiskus, W ;

Yamaguchi, H ;

Balasis, M ;

Rocha, K ;

Wang, HG ;

Richon, V ;

Bhalla, K .

CLINICAL CANCER RESEARCH, 2005, 11 (17) :6382-6389

[7]

Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544

[8] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[9] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[10] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].

Buzdar, AU ;

Ibrahim, NK ;

Francis, D ;

Booser, DJ ;

Thomas, ES ;

Theriault, RL ;

Pusztai, L ;

Green, MC ;

Arun, BK ;

Giordano, SH ;

Cristofanilli, M ;

Frye, DK ;

Smith, TL ;

Hunt, KK ;

Singletary, SE ;

Sahin, AA ;

Ewer, MS ;

Buchholz, TA ;

Berry, D ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685

← 1 2 3 4 5 6 7 8 →